- Conditions
- Subjects With Varying Degrees of Renal Insufficiency and, Subjects With Normal Renal Function
- Interventions
- RPX7009 and RPX2014
- Drug
- Lead sponsor
- Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 2
- States / cities
- Lakewood, Colorado • Minneapolis, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1225–1248
of 6,446
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Oligoprogressive Renal Cell Carcinoma
- Interventions
- Stereotactic ablative body radiation (SABR)
- Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Anemia
- Interventions
- Epoetin Alfa
- Drug
- Lead sponsor
- Mehrotra, Anita, M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Kidney Insufficiency, Chronic
- Interventions
- Not listed
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- End Stage Kidney Disease
- Interventions
- Standard Table Salt, Salt Substitute
- Dietary Supplement
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Idiopathic Membranous Nephropathy
- Interventions
- Rituximab, Cyclosporine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 13 more
- Conditions
- Chronic Kidney Failure, HIV Infection
- Interventions
- immunosuppressive regimen designed to complement HAART
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Idiopathic Membranous Nephropathy
- Interventions
- Aliskiren
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Ureteral Calculus, Ureterolithiasis, Ureteral Stone
- Interventions
- Silodosin, Tamsulosin
- Drug
- Lead sponsor
- Albert Einstein Healthcare Network
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Renal Cell Carcinoma (RCC)
- Interventions
- Trans-arterial embolization (TAE)
- Procedure
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Stanford, California • Rochester, Minnesota + 1 more
- Conditions
- Chronic Kidney Disease, Depression
- Interventions
- Sertraline, placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Autoimmune Diseases
- Interventions
- Efalizumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- E/C/F/TDF, COBI, ATV, DRV, NRTI
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
- Conditions
- Chronic Periodontitis, End Stage Renal Disease
- Interventions
- Test
- Other
- Lead sponsor
- UConn Health
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Hemodialysis-Induced Symptom, Mitochondrial Diseases
- Interventions
- Icatibant, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 78 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Catheter-Related Infections
- Interventions
- (taurolidine and heparin) catheter lock solution, Standard of Care
- Drug
- Lead sponsor
- CorMedix Therapeutics
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 3 more
- Conditions
- Diabetes Mellitus
- Interventions
- Insulin, Isophane, insulin glargine
- Drug
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Falls Church, Virginia
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- panobinostat, everolimus, laboratory biomarker analysis, pharmacological study, liquid chromatography, mass spectrometry, enzyme-linked immunosorbent assay, immunohistochemistry staining method
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Rochester, New York
- Conditions
- Delayed Graft Function
- Interventions
- ANG-3777, Placebo
- Drug · Other
- Lead sponsor
- Angion Biomedica Corp
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 24 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- CRLX101 (Cerulean), Bevacizumab
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic Kidney Disease
- Interventions
- EC5026 oral tablet
- Drug
- Lead sponsor
- EicOsis Human Health Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Metastatic Malignant Neoplasm
- Interventions
- NPX267
- Drug
- Lead sponsor
- NextPoint Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • New York, New York + 4 more
- Conditions
- IgA Nephropathy
- Interventions
- Placebo, Atacicept 25 mg, Atacicept 75 mg
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 16
- States / cities
- Glendale, Arizona • Chula Vista, California • Denver, Colorado + 13 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer, Prostate Cancer
- Interventions
- MDX-1106
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Detroit, Michigan • St Louis, Missouri + 1 more